Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis

• Published in: Journal of gastroenterology Vol. 57; no. 9; pp. 684 - 694
• Main Authors: Zhou, Qunfang, Wang, Xiaohui, Li, Ruixia, Wang, Chenmeng, Wang, Juncheng, Xie, Xiaoyan, Li, Yali, Li, Shaoqiang, Mao, Xianhai, Liang, Ping
• Format: Journal Article
• Language: English
• Published: Singapore Springer Nature Singapore 01.09.2022; Springer Nature B.V
• Subjects: Abdominal Surgery; Ablation; Adjuvant therapy; Biliary Tract; Colorectal Surgery; Gastroenterology; Hepatectomy; Hepatocellular carcinoma; Hepatology; Inhibitor drugs; Liver cancer; Medicine; Medicine & Public Health; Original Article―Liver; Original ―Liver, Pancreas, and Biliary Tract; Pancreas; Radiofrequency ablation; Surgical Oncology; Survival; Targeted cancer therapy; Radiofrequency ablation; Milan criteria; Prognosis; Sorafenib; Recurrent hepatocellular carcinoma

Background Radiofrequency ablation (RFA) is considered as a convenient treatment with mild damage in treating recurrent hepatocellular carcinoma (RHCC). However, for patients with high risk of progression after RFA still needs new strategies to decrease the repeat recurrence. Methods A total of 460...